Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials.
Authors
Rishi Surana
Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Rishi Surana , Jane E. Rogers , Graciela M. Nogueras-Gonzalez , David S. Hong , Timothy A. Yap , Jordi Rodon Ahnert , Aung Naing , Robert A. Wolff , Brandon George Smaglo , Funda Meric-Bernstam , Vivek Subbiah , Shubham Pant
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.577
Abstract #
577
Poster Bd #
J6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
First Author: Yu Fujiwara
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2022 ASCO Genitourinary Cancers Symposium
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
First Author: Sophie Laramee
Poster
2021 ASCO Annual Meeting
Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.
First Author: Nadia Hindi